Assembly Biosciences (STU:V7B) Cyclically Adjusted Book per Share: €50.76 (As of Mar. 2026)


STU:V7B Assembly Biosciences Inc STU:V7B
31 GF Score
Price €24.00
GF Value €17.38
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Cyclically Adjusted Book per Share?

Assembly Biosciences STU:V7B -1.23% 31 Cyclically Adjusted Book per Share is €50.76 as of Mar. 2026. GuruFocus rates STU:V7B with a GF Score™ of 31/100 and a GF Value™ of €17.38 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Assembly Biosciences's adjusted book value per share for the three months ended in Mar. 2026 was €10.810. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €50.76 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Assembly Biosciences's average Cyclically Adjusted Book Growth Rate was -12.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -10.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Assembly Biosciences was 10.10% per year. The lowest was -10.00% per year. And the median was -7.30% per year.

As of today (2026-07-11), Assembly Biosciences's current stock price is €24.00. Assembly Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €50.76. Assembly Biosciences's Cyclically Adjusted PB Ratio of today is 0.47.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Assembly Biosciences was 5.22. The lowest was 0.10. And the median was 0.39.


Assembly Biosciences  (STU:V7B) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Assembly Biosciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=24.00/50.76
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Assembly Biosciences was 5.22. The lowest was 0.10. And the median was 0.39.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Assembly Biosciences Cyclically Adjusted Book per Share Related Terms


Assembly Biosciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Assembly Biosciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences Cyclically Adjusted Book per Share Chart

Assembly Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 72.67 75.79 69.31 61.93 48.48

Assembly Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.83 54.59 49.68 48.48 50.76

STU:V7B vs CTNM, PRTA, RGNX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Assembly Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Cyclically Adjusted PB Ratio falls into.


STU:V7B
31GF Score
Assembly Biosciences Inc STU:V7B
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Assembly Biosciences's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=10.81/330.2130*330.2130
=10.810

Current CPI (Mar. 2026) = 330.2130.

Assembly Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201606 62.369 241.018 85.450
201609 55.909 241.428 76.470
201612 52.696 241.432 72.074
201703 43.988 243.801 59.579
201706 34.773 244.955 46.876
201709 27.291 246.819 36.512
201712 56.964 246.524 76.302
201803 48.871 249.554 64.667
201806 44.395 251.989 58.176
201809 92.660 252.439 121.208
201812 87.136 251.233 114.529
201903 79.147 254.202 102.813
201906 72.352 256.143 93.274
201909 65.905 256.759 84.759
201912 90.636 256.974 116.468
202003 83.799 258.115 107.206
202006 86.759 257.797 111.130
202009 83.708 260.280 106.199
202012 69.730 260.474 88.399
202103 62.144 264.877 77.473
202106 52.738 271.696 64.097
202109 48.674 274.310 58.594
202112 37.282 278.802 44.157
202203 33.230 287.504 38.166
202206 29.103 296.311 32.433
202209 25.601 296.808 28.482
202212 19.150 296.797 21.306
202303 15.154 301.836 16.579
202306 11.603 305.109 12.558
202309 8.914 307.789 9.563
202312 6.873 306.746 7.399
202403 5.470 312.332 5.783
202406 5.077 314.175 5.336
202409 3.687 315.301 3.861
202412 4.272 315.605 4.470
202503 3.294 319.799 3.401
202506 2.045 322.561 2.094
202509 9.841 324.800 10.005
202512 11.136 324.054 11.348
202603 10.810 330.213 10.810

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €50.76 mean?
Assembly Biosciences (STU:V7B) has a Cyclically Adjusted Book per Share of €50.76 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Assembly Biosciences and its competitors.
Is Assembly Biosciences' Cyclically Adjusted Book per Share too high?
Assembly Biosciences' current Cyclically Adjusted Book per Share is €50.76. Overall, Assembly Biosciences has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Cyclically Adjusted Book per Share compare to CTNM and PRTA?
Assembly Biosciences' Cyclically Adjusted Book per Share of €50.76 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current Cyclically Adjusted Book per Share is €50.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Assembly Biosciences (STU:V7B) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.38, compared to a current price of €24.00 — trading 38.1% above its estimated fair value. The current Cyclically Adjusted Book per Share is €50.76. Assembly Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Assembly Biosciences (STU:V7B), the current Cyclically Adjusted Book per Share is €50.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Assembly Biosciences (STU:V7B) Overvalued in 2026?

Based on GuruFocus' analysis, Assembly Biosciences stock appears to be overvalued. The current stock price of €24.00 is trading 38.1% above its estimated GF Value™ of €17.38. GuruFocus considers Assembly Biosciences to be Significantly Overvalued.

Key valuation signals for STU:V7B:

  • Cyclically Adjusted Book per Share: €50.76
  • GF Value™: €17.38 vs. price of €24.00 (38.1% above fair value)
  • GF Score™: 31/100 with 3 warning signs

No single metric tells the full story. See the STU:V7B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Assembly Biosciences Business Description

Other Exchanges ASMB:USA
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score

Get the complete analysis for STU:V7B

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.00
Price
€17.38
GF Value